Clinical Trials
4 trialsNCT01486784 2021-06-24
A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia
Abramson Cancer Center at Penn Medicine
Phase 1/2 Terminated
NCT02587962 2021-01-14
Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors
Medivir
Phase 1/2 Terminated
NCT01681368 2017-05-30
Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01188499 2016-05-30
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
TetraLogic Pharmaceuticals
Phase 1/2 Completed